Nicotinamide mononucleotide (NMN) supplementation has garnered interest for its potential health benefits, especially in anti-aging and metabolic support, though evidence in humans remains limited. While animal studies, particularly in mice, suggest NMN may improve metabolic functions, human trials to date have shown modest or inconclusive results.

The first human study on NMN, conducted in Japan in 2020, primarily assessed safety and reported no serious adverse effects. A subsequent randomized controlled trial in 2021 involving postmenopausal women with prediabetes found that daily supplementation of 250 mg of NMN for ten weeks led to slight improvements in insulin sensitivity in skeletal muscle. However, the study did not demonstrate meaningful changes in glucose tolerance, body weight, lipid profiles, or markers of inflammation. Other small-scale studies have linked NMN intake with subjective improvements in fatigue, sleep quality, or exercise capacity, but none have confirmed reductions in mortality, delayed onset of age-related illnesses, or lifespan extension.

Concerns persist regarding the safety profile of NMN. Because it enhances NAD-related processes involved in DNA repair, there is a theoretical risk it may also promote increased cell division, which could raise cancer risk. Experts note that data on NMN’s effects in pregnant individuals or cancer patients are insufficient, leading some governments, including China’s, to adopt a cautious regulatory stance.

Separately, the expanding wellness industry, fueled in part by medical uncertainty and public anxiety over health, has popularized various screening tests and supplements, sometimes beyond well-established medical guidelines. Prostate cancer screening using the prostate-specific antigen (PSA) test illustrates the complexity. PSA testing can detect elevated protein levels associated with prostate cancer, potentially identifying disease at an earlier, more treatable stage. Yet, many non-cancerous conditions—such as benign prostate enlargement, infections, or even recent sexual activity—can also elevate PSA levels, resulting in false positives.

Research has shown that less than 30% of men with a positive PSA test are confirmed to have cancer upon biopsy. Moreover, some prostate cancers remain undetected because they do not significantly raise PSA levels. This dual challenge means PSA testing can both overdiagnose men without cancer and miss those with it. Given that many prostate cancers grow slowly and may never become life-threatening, the clinical management of positive cases is often complex, with some patients opting for monitoring instead of immediate treatment.

The private blood-testing industry has expanded notably over the past decade, driven by easier access challenges within national health services and aggressive marketing online. These services encourage healthy individuals to check numerous biomarkers, many of which fluctuate naturally and can yield abnormal results without indicating disease. Experts caution that overtesting may lead to unnecessary anxiety, follow-up procedures, and increased burden on public healthcare systems.

Another area of growth is testosterone therapy, which has seen a sharp increase in prescriptions in recent years despite stable prevalence of clinically low testosterone levels among men. While testosterone replacement can effectively address sexual dysfunction and is essential for some individuals unable to produce the hormone naturally, unwarranted use carries risks. High doses may increase cardiovascular problems, liver issues, and mood disturbances, and could suppress natural hormone production, leading to dependence on lifelong therapy.

Medical specialists advise patients considering testosterone treatment to seek evaluation from independent healthcare providers not affiliated with wellness marketing and to weigh costs against benefits. They also stress that evidence-based national screening programs—such as those for breast, cervical, and bowel cancers—along with routine dental and eye exams, remain crucial components of preventive care accessible without additional private expense.

In sum, while supplements like NMN hold promise, currently available human data do not support broad claims of substantial benefit, and screening tests carry limitations that require careful interpretation. Individuals are encouraged to consult qualified healthcare professionals before pursuing private testing or therapies and to prioritize established health programs.